It is critical to note that microdosing is not recommended by the FDA, and no research studies have been conducted yet to test its effectiveness and safety
These medications were initially developed for type 2 diabetes, and more recently have been approved for weight management, because they can reduce appetite, slow gastric emptying, and improve insulin sensitivity
As a triple agonist, retatrutide activates GLP-1, GIP, and glucagon pathways producing greater metabolic effects than single-acting GLP-1 drugs
Continuous 28C from pharmacy release to your front door no transcontinental shipping, no anonymous handoffs, no broken cold-chain
Additional indications under investigation include type 2 diabetes management and metabolic dysfunction-associated steatohepatitis
Weight loss should not feel like a constant struggle or a cycle of trial and error